What Do the Next 5 Years Hold for Radiopharmaceuticals?
Radiopharmaceutical studies are still evolving and still ultra-complex. There’s a lot to learn for the entire industry, and even small pitfalls can mean huge delays and budget overruns for your study.
This demanding field calls for an expert — someone who’s pioneered it and delivered similar studies time and again.
Join us for an exclusive look at what’s to come and how to position your study for success.
Webinar Details
Addressing current roadblocks in manufacturing, distribution, and site identification is essential for optimizing radiopharmaceutical development. Following the positive response from attendees at the recent TRP Summit, we’re excited to share this session with a broader audience.
The art of running radiopharmaceutical studies lies in “informed foresight” — not only the expertise to pivot when challenges arise, but to account for the unique challenges of this drug class from day one.
As the CRO that delivered the first-ever targeted radioligand therapy to market, PSI has continually pioneered clinical research in the rapidly expanding radiopharmaceutical sector. Join us for an in-depth look at how to manage the challenges to come with Dylan Stoy, Director of Therapeutic Strategy, RLT.
Watch now to:
- Learn how the industry has evolved over the past 5 years
- Understand where the industry must scale to meet the growing demand
- Gain insights into how to prepare for the next 5 years of innovation
Speakers
Dylan Stoy
Director of Therapeutic Strategy, RLT
PSI CRO
Dylan Stoy is dedicated to conducting and executing better clinical studies in PSI’s core therapeutic areas. Dylan has worked in radiopharmaceutical research for over 10 years, with research interests in targeted drug delivery systems and optimizing the conduct of studies. Dylan has overseen radiopharmaceutical research from various roles, including onsite research, design and trial conduct, clinical operations oversight, project management, and therapeutic strategy.
